Why Choose the Myeloma Institute?
- Recognized Worldwide for Innovation and Cure. The UAMS Myeloma Institute for Research and Therapy is an international leader in the treatment and study of multiple myeloma and related diseases. Our team of dynamic scientists and clinicians translates advances from the laboratory into novel clinical treatments, continually expanding the boundaries of myeloma research and therapy toward cure for all patients.
- Experience. The Myeloma Institute has a 30-year history of clinical and research knowledge and experience uniquely focused on a single disease—multiple myeloma—and related conditions. The Myeloma Institute sees more patients with myeloma and related diseases per year than any other institution in the world. In fact, on any given day there are at least 320 myeloma patients staying in Little Rock for diagnosis and treatment of their disease.
Maurizio Zangari, MD
- Expertise. The Myeloma Institute’s multidisciplinary team approach gives patients access to comprehensive, highly specialized care, tailoring special individualized treatment plans for each patient’s myeloma. We have a dedicated supportive care team for the management of disease and treatment complexities and extensive network of support services to facilitate visits for patients traveling to Little Rock.
- Our Novel “Total Therapy” Approach is designed to attack myeloma up front with a full array of treatment modalities.
- Gene Array Analysis. The Myeloma Institute routinely offers state-of-the-art genetic profiling to molecularly characterize a patient’s disease and then translate those findings into the most advanced individualized treatment strategies available today.
- Proven results. Our world-class physicians and scientists employ novel, new technologies and treatments, resulting in continually improved survival durations and survival rates. A patient newly diagnosed with low-risk multiple myeloma who is treated at the Myeloma Institute can expect to survive more than 10 years. The currently expected 5-year survival rate for a newly-diagnosed multiple myeloma patient treated at the Myeloma Institute is 74%, versus 43% for a comparable population in the National Cancer Institute cancer statistics (SEER) database (based on comparison of overall survival for Total Therapy 3 patients with overall survival for myeloma patients in the SEER data base who were diagnosed in or after 2003; age less than 75 at time of diagnosis).
- Ground-breaking research. A world leader in multiple myeloma research, the Myeloma Institute continues to develop new treatments for multiple myeloma and related diseases. Researchers conduct robust clinical trials that incorporate novel treatment approaches to push beyond past successes and further improve patient outcomes. Over 1100 patients participated in clinical trials in Fiscal Year 2013.